Mental Health & Neurodegeneration Research Group, School of Community Based Medicine, The University of Manchester, Manchester, UK.
Int J Psychiatry Clin Pract. 2012 Jun;16(2):148-52. doi: 10.3109/13651501.2011.625122. Epub 2011 Oct 31.
The aim of the study was to investigate sexual function in patients with schizophrenia receiving treatment with a first-generation antipsychotic (FGA) or a second-generation antipsychotic (SGA) drug. Sexual function is an important aspect of human experience, which can be affected by antipsychotic drug treatment. Sexual dysfunction in patients with schizophrenia may be less prevalent with SGA than with FGA drug treatment.
A cross-sectional prevalence study assessed sexual function in a sample of 144 patients with DSM-IV schizophrenia aged between 18 and 65, using the Derogatis Interview for Sexual Functioning (self-report version: DISF-SR). Two equal-sized groups (N = 72) received treatment with an FGA or an SGA drug for at least 12 weeks.
No significant differences were seen on DISF-SR total score or subscale score between the two treatment groups.
There are no differences in measured sexual function of non-randomised patients with schizophrenia treated with an FGA compared with SGA-treated patients.
本研究旨在探讨接受第一代抗精神病药物（FGA）或第二代抗精神病药物（SGA）治疗的精神分裂症患者的性功能。性功能是人类体验的一个重要方面，可能会受到抗精神病药物治疗的影响。与 FGA 药物治疗相比，SGA 治疗可能会降低精神分裂症患者的性功能障碍发生率。
采用横断面患病率研究，使用性功能障碍访谈（自我报告版：DISF-SR）评估了 144 名年龄在 18 至 65 岁之间的 DSM-IV 精神分裂症患者的性功能。将患者分为两组（每组 N = 72），两组患者均接受至少 12 周的 FGA 或 SGA 药物治疗。
两组患者在 DISF-SR 总分或子量表评分上均无显著差异。
在未随机分组的精神分裂症患者中，与 SGA 治疗组相比，FGA 治疗组的性功能无差异。
Zotero 插件